Aeterna Zentaris Enters into Licensing and Assignment Agreement with Strongbridge for Macrilen™ (macimorelin) in the U.S. and Canada
January 17, 2018 07:00 ET
|
Aeterna Zentaris Inc.
CHARLESTON, S.C., Jan. 17, 2018 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) announced today that it has, through a wholly-owned subsidiary, entered into a license and...
Aeterna Zentaris Provides Update on Litigation against David Dodd and Philip Theodore
December 22, 2017 16:15 ET
|
Aeterna Zentaris Inc.
CHARLESTON, S.C., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (the “Company” or “Aeterna Zentaris”) (NASDAQ:AEZS) (TSX:AEZS), a specialty biopharmaceutical company engaged in developing...
Aeterna Zentaris Announces FDA Approval of Macrilen™ (macimorelin) for Diagnosis of Adult Growth Hormone Deficiency
December 20, 2017 17:00 ET
|
Aeterna Zentaris Inc.
CHARLESTON, S.C., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS), a specialty biopharmaceutical company engaged in developing and commercializing pharmaceutical...
Aeterna Zentaris Announces Departure of Interim Chief Financial Officer
December 08, 2017 08:00 ET
|
Aeterna Zentaris Inc.
CHARLESTON, S.C., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) (the “Company”) announced today the departure of the Company’s Interim Chief Financial...
Aeterna Zentaris’ Marketing Authorization Application for Macrilen™ (macimorelin) for Evaluation of Adult Growth Hormone Deficiency Accepted by European Medicines Agency
November 27, 2017 16:41 ET
|
Aeterna Zentaris Inc.
CHARLESTON, S.C., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) announced that the Marketing Authorization Application (“MAA”) for the use of Macrilen™...